FDA warns about risks of compounded ketamine products for at-home use
The FDA issued a safety alert regarding compounded ketamine products — including oral formulations marketed through telemedicine platforms for at-home use — noting that compounded drugs are not FDA-approved, that sedation and dissociation can occur without monitoring, and that psychiatric and urinary adverse events have been reported.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Record details
- Agency
- FDA
- Jurisdiction
- United States (federal)
- Status
- Guidance / alert
- Published
- October 10, 2023
- Effective
- Not applicable / not verified
- Expires
- Not applicable / not verified
- Last checked
- August 24, 2026
Why it matters
This alert is the clearest federal statement on the at-home ketamine model and is directly relevant to anyone evaluating a mail-order telehealth program.
Primary source
FDA — Compounding Risk Alerts (includes the October 2023 compounded ketamine alert)
Back to the Regulatory Tracker.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.